Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178984973> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3178984973 endingPage "102994" @default.
- W3178984973 startingPage "102994" @default.
- W3178984973 abstract "Patients with MS have increased risk of infections, especially those with highly active treatments. We studied the safety of natalizumab in patients with MS during the COVID-19 pandemic. Demographic features, time on natalizumab, dose interval and COVID-19 symptoms were evaluated in a prospective study of patients with MS receiving natalizumab during the pandemic. RT-PCR COVID-19 tests from nasopharyngeal samples were performed before natalizumab treatment. We analyzed 69 patients: 71% women, mean age 43 years. Mean treatment duration was 68 months (range: 2–141). In 32% of patients, natalizumab regimen was changed from every 4 to every 6 weeks to decrease number of hospital visits. From March to April 2020, 5 patients had COVID-19, 4 showed mild symptoms and 1 a multi-lobar pneumonia. On May 2020, we started COVID-19 screening before natalizumab infusion. From May 2020 to March 2021, tests were performed on 553 nasopharyngeal swabs. Fourteen patients had a positive result and natalizumab was stopped; tests were repeated 1–2 weeks later, with negative results, and natalizumab was restarted. In summary: 19 patients had COVID-19, 10 asymptomatic, 7 mild symptoms, 2 pneumonia (1 of whom hospitalized without mechanical ventilation). There were no statistically significant differences in age (mean±standard deviation, 35.7±11.5 vs 43.4±7.8 years; p=0.158), dose interval (5.33 vs 5.32 weeks; p=0.962) or treatment duration (5.8 vs 5.6 years; p=0.298) between patients with and without COVID-19. Natalizumab treatment in MS seems to be safe during the pandemic. Most patients were asymptomatic, and no patient required mechanical ventilation." @default.
- W3178984973 created "2021-07-19" @default.
- W3178984973 creator A5016835291 @default.
- W3178984973 creator A5025254958 @default.
- W3178984973 creator A5052192745 @default.
- W3178984973 creator A5059459213 @default.
- W3178984973 creator A5079994006 @default.
- W3178984973 creator A5088301395 @default.
- W3178984973 date "2021-06-01" @default.
- W3178984973 modified "2023-10-10" @default.
- W3178984973 title "Is natalizumab a safe treatment for patients with multiple sclerosis in the COVID-19 pandemic? Data from the first year of the pandemic" @default.
- W3178984973 doi "https://doi.org/10.1016/j.msard.2021.102994" @default.
- W3178984973 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8250634" @default.
- W3178984973 hasPublicationYear "2021" @default.
- W3178984973 type Work @default.
- W3178984973 sameAs 3178984973 @default.
- W3178984973 citedByCount "0" @default.
- W3178984973 crossrefType "journal-article" @default.
- W3178984973 hasAuthorship W3178984973A5016835291 @default.
- W3178984973 hasAuthorship W3178984973A5025254958 @default.
- W3178984973 hasAuthorship W3178984973A5052192745 @default.
- W3178984973 hasAuthorship W3178984973A5059459213 @default.
- W3178984973 hasAuthorship W3178984973A5079994006 @default.
- W3178984973 hasAuthorship W3178984973A5088301395 @default.
- W3178984973 hasBestOaLocation W31789849732 @default.
- W3178984973 hasConcept C126322002 @default.
- W3178984973 hasConcept C203014093 @default.
- W3178984973 hasConcept C2777910003 @default.
- W3178984973 hasConcept C2777914695 @default.
- W3178984973 hasConcept C2779134260 @default.
- W3178984973 hasConcept C2780640218 @default.
- W3178984973 hasConcept C2781004633 @default.
- W3178984973 hasConcept C2781413609 @default.
- W3178984973 hasConcept C3008058167 @default.
- W3178984973 hasConcept C524204448 @default.
- W3178984973 hasConcept C71924100 @default.
- W3178984973 hasConcept C89623803 @default.
- W3178984973 hasConceptScore W3178984973C126322002 @default.
- W3178984973 hasConceptScore W3178984973C203014093 @default.
- W3178984973 hasConceptScore W3178984973C2777910003 @default.
- W3178984973 hasConceptScore W3178984973C2777914695 @default.
- W3178984973 hasConceptScore W3178984973C2779134260 @default.
- W3178984973 hasConceptScore W3178984973C2780640218 @default.
- W3178984973 hasConceptScore W3178984973C2781004633 @default.
- W3178984973 hasConceptScore W3178984973C2781413609 @default.
- W3178984973 hasConceptScore W3178984973C3008058167 @default.
- W3178984973 hasConceptScore W3178984973C524204448 @default.
- W3178984973 hasConceptScore W3178984973C71924100 @default.
- W3178984973 hasConceptScore W3178984973C89623803 @default.
- W3178984973 hasLocation W31789849731 @default.
- W3178984973 hasLocation W31789849732 @default.
- W3178984973 hasOpenAccess W3178984973 @default.
- W3178984973 hasPrimaryLocation W31789849731 @default.
- W3178984973 hasRelatedWork W1985660084 @default.
- W3178984973 hasRelatedWork W1989037087 @default.
- W3178984973 hasRelatedWork W2037777985 @default.
- W3178984973 hasRelatedWork W2151867003 @default.
- W3178984973 hasRelatedWork W2164906127 @default.
- W3178984973 hasRelatedWork W2948529275 @default.
- W3178984973 hasRelatedWork W3016997033 @default.
- W3178984973 hasRelatedWork W4255590419 @default.
- W3178984973 hasRelatedWork W4307344424 @default.
- W3178984973 hasRelatedWork W4311483557 @default.
- W3178984973 hasVolume "51" @default.
- W3178984973 isParatext "false" @default.
- W3178984973 isRetracted "false" @default.
- W3178984973 magId "3178984973" @default.
- W3178984973 workType "article" @default.